Effects of statins on progression of carotid atherosclerosis as measured by carotid intimal-medial thickness: A meta-analysis of randomized controlled trials

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 15, Issue 3, 2010, Pages 268-273

  Bedi, Updesh Singh ^a,b   Singh, Mukesh ^a   Singh, Param Puneet ^a   Bhuriya, Rohit ^a   Bahekar, Amol ^a   Molnar, Janos ^a   Khosla, Sandeep ^a   Arora, Rohit ^a  

^a The Chicago Medical College   (United States)

^b MOUNT SINAI HOSPITAL   (United States)

Author keywords

atherosclerosis; carotid intimal media thickness; statins

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; CAROTID ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; ECHOGRAPHY; FOLLOW UP; HUMAN; META ANALYSIS; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

CAROTID ARTERIES; CAROTID ARTERY DISEASES; CHOLESTEROL, LDL; DISEASE PROGRESSION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TUNICA INTIMA;

EID: 77956864643     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248410369110     Document Type: Article

References (34)

1. Chambless LE, Zhong MM, Arnett D., Folsom AR, Riley WA, Heiss G. Variability in B-mode ultrasound measurements in the atherosclerosis risk communities (ARIC) study. Ultrasound Med Biol. 1996 ; 22 (5). 545-554.
2. Mannami T., Konishi M., Baba S., Nishi N., Terao A. Prevalence of asymptomatic carotid atherosclerotic lesions detected by high-resolution ultrasonography and its relation to cardiovascular high risk factors in the general population of a Japanese city: the Suita study. Stroke. 1997 ; 28 (3). 518-525.
3. Smilde TJ, van den Berkmortel FW, Boers GH, et al. Carotid and femoral wall thickness and stiffness in patients at risk for cardiovascular disease, with special emphasis on hyperhomocysteinemia. Arterioscler Thromb Vasc Biol. 1998 ; 18 (12). 1958-1963.
4. Bots ML, Breslau PJ, Brit E., et al. Cardiovascular determinants of carotid artery disease: the Rotterdam Elderly Study. Hypertension. 1992 ; 19 (6 pt 2). 717-720.
5. Burke GL, Evans GW, Riley WA, et al. Arterial wall thickness is associated with prevalent cardiovascular disease in middle aged adults: the Atheorsclerosis Risk in Communities (ARIC) study. Stroke. 1995 ; 26 (3). 386-391.
6. Chambless LE, Heiss G., Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerotic Risk in Communities (ARIC) study, 1987-1993. Am J Epidemiol. 1997 ; 146 (6). 483-494.
7. Hodis HN, Mack WJ, LaBree L., et al. The role of carotid arterial intima media thickness in predicting clinical coronary events. Ann Intern Med. 1998 ; 128 (4). 262-269.
8. Hodis HN, Mack WJ, LaBree L., et al. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomised, controlled clinical trial. Ann Intern Med. 1996 ; 24 (6). 548-556.
9. Kroon AA, Asten van Wnjc, Stalenhoef AFH. Effects of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolaemic patients with coronary artery disease. Ann Intern Med. 1996 ; 125 (12). 945-954.
10. Furberg CD, Adams HP Jr, Applegate WB, et al for the Asymptomatic Carotid Artery Progression Study (ACAPS) research group. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation. 1994 ; 90 (4). 1679-1687.
11. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994 ; 344 (8934). 1383-1389.
12. Shepherd J., Cobbe SM, Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995 ; 333 (20). 1301-1307.
13. Sacks FM, Pfeffer MA, Moyé LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996 ; 336 (13). 1001-1009.
14. Blauw GJ, Lagaay AM, Smelt AHM, Westendorp RGJ. Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke. 1997 ; 28 (5). 946-950.
15. Crouse JR III, Byington RP, Hoen HM, Furberg CD Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med. 1997 ; 157 (12). 1305-1310.
16. Hebert PR, Gaziano JM, Chan KS, Hennekens CH Cholesterol-lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. J Am Med Assoc. 1997 ; 278 (4). 313-321.
17. Moher D., Cook DJ, Eastwood S., Olkin I., Rennie D., Stroup DF Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet. 1999 ; 354 (9193). 1896-1900.
18. Crouse JR, Raichlen JS, Riley WA, et al. for the METEOR study group. Effect of rosuvastatin on progression of carotid intimamedia thickness in low-risk individuals with subclinical atherosclerosis. The METEOR Trial. JAMA. 2007 ; 297 (6). 1344-1353.
19. Smilde TJ, van Wissen S., Wollersheim H., Trip MD, Kastelein JJP, Stalanhoef AFH. Effects of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP). Lancet. 2001 ; 357 (8). 577-581.
20. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness (ARBITER). Circulation. 2002 ; 106 (3). 2055-2060.
21. Takahashi T., Ishii N., Itai K., Goto R., Higashi K., Kobori S. HMGCoA reductase inhibitors suppress the development and progression of carotid artery intimal medial thickening in hypercholesterolemic type 2 diabetic patients. J Atheroscler Thromb. 2005 ; 12 (6). 149-153.
22. MacMahon S., Sharpe N., Gamble G., et al. Effects of Lowering Average or Below-Average Cholesterol Levels on the Progression of Carotid Atherosclerosis: Results of the LIPID Atherosclerosis Substudy. Circulation. 1998 ; 97 (8). 1784-1790.
23. Hedblad B., Wikstrand J., Janzon L., Wedel H., Berglund G. Low-Dose Metoprolol CR/XL and Fluvastatin Slow Progression of Carotid Intima-Media Thickness: Main Results From the 2-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation. 2001 ; 103 (1). 1721-1726.
24. Yu CM, Zhang Q., Lam L., et al. Comparison of intensive and low-dose atorvastatin therapy in the reduction of carotid intimal-medial thickness in patients with coronary heart disease. Heart. 2007 ; 93 (7). 933-939.
25. Groot E., Jukema JW, van Swijndregt ADM, et al. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS). J Am Coll Cardiol. 1998 ; 31 (4). 1561-1567.
26. Touboul PJ, Elbaz A., Koller C., et al. on behalf of the GENIC Investigators. Common carotid artery intimamedia thickness and brain infarction: The Etude du Profile Genetique de l Infarctus Cerebral (GENIC) case-control study Circulation. 2000 ; 102 (5). 313-318.
27. Touboul PJ, Hennerici MG, Meairs S., et al. Mannheim carotid intima-media thickness consensus (2004-2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis. 2007 ;23(8): 75-80.
28. Stein JH, Korcarz CE, Hurst RT, et al. American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid IntimaMedia Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr. 2008 ; 21 (10). 93-112.
29. Aviram M., Dankner G., Cogan U., Hochgraf E., Brook G. Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: in vitro and in vivo studies. Metabolism. 1992 ; 41 (18). 229-235.
30. Sindermann JR, Fan L., Weigel KA, et al. Differences in the effects of HMG-CoA reductase inhibitors on proliferation and viability of smooth muscle cells in culture. Atherosclerosis. 2000 ; 150 (3). 331-341.
31. Sakai M., Miyazaki A., Hakamata H., et al. Lysophosphatidylcholine plays an essential role in the mitogenic effect of oxidized low density lipoprotein on murine macrophages. J boil Chem. 1994 ; 269 (6). 31430-31435.
32. Sakai M., Miyazaki A., Hakamata H., et al. Lysophosphatidylcholine potentiates the mitogenic activity of modified LDL for Human Monocyte derived Macrophages. Arterioscler Thromb Vasc Biol. 1996 ; 16 (2). 600-605.
33. Sakai M., Kobori S., Matsumura T., et al. HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein. Atherosclerosis. 1997 ; 133 (6). 51-59.
34. Amarenco P., Labreuche J., Lavallee Touboul PJ Statins in stroke prevention and carotid atherosclerosis. Stroke. 2004 ; 35 (12). 2902-2909.